InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #canaccord--InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time. The...

Click to view original post